Premium
A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2‐arachidonoylglycerol with potential anti‐obesity effects
Author(s) -
Bisogno Tiziana,
Mahadevan Anu,
Coccurello Roberto,
Chang Jae Won,
Allarà Marco,
Chen Yugang,
Giacovazzo Giacomo,
Lichtman Aron,
Cravatt Benjamin,
Moles Anna,
Di Marzo Vincenzo
Publication year - 2013
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.12013
Subject(s) - monoacylglycerol lipase , endocannabinoid system , fatty acid amide hydrolase , 2 arachidonoylglycerol , diacylglycerol lipase , chemistry , cannabinoid receptor , cannabinoid , pharmacology , biochemistry , receptor , antagonist , biology
The development of potent and selective inhibitors of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG) via DAG lipases (DAGL) α and β is just starting to be considered as a novel and promising source of pharmaceuticals for the treatment of disorders that might benefit from a reduction in endocannabinoid tone, such as hyperphagia in obese subjects.